All In Biotech

Drug Trial Radar · NCT03257241

A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old

Last checked: Nov 20, 2026Latest source record: Oct 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 582 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

582

Planned (sponsor's estimate)

Start

Jul 3, 2017

Primary completion

Apr 1, 2022

Study completion Dec 31, 2022

Sponsor

Lead sponsor
Polish Adult Leukemia GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 22, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will include newly-diagnosed AML patients, not suffering acute promyelocytic leukemia; aged 18-60 years, who are eligible for standard induction chemotherapy. The patients will be randomized to one standard induction regimen (DAC or DA-90). At day seven after completion of induction, a bone marrow aspiration with MRD will be performed for an early evaluation of response to treatment. Patients without bone marrow blast reduction below 10% at day seven after induction will be given a second early induction course. Patients who do not achieve CR after two induction courses will be randomized to one of the standard salvage regimens (FLAG-IDA or CLAG-M). Postremission treatment intensity will be adjusted to risk group based on cytogenetic and molecular risk factors at diagnosis and AML biology (secondary AML, therapy related AML). Patients with a low risk of relapse will be allocated to consolidation, with three courses of high doses of Ara-C (HiDAC), or two courses of HiDAC with subsequent autologous stem cell transplantation. Intermediate- or high-risk patients will be referred for allogeneic stem cell transplantation, if they have a matched donor. Until transplantation, consolidation with HiDAC will be continued.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • A arm (DA-90)Drug

    After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is \> 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.

  • B arm (DAC)Drug

    After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is \> 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.

  • A arm (CLAG-M)Drug

    Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment ("salvage") according to the CLAG- M or FLAG-IDA protocol.

  • B arm (FLAG-IDA)Drug

    Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment ("salvage") according to the CLAG- M or FLAG-IDA protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Induction regimen efficacy (DA-90 vs DAC) - I inductionTime frame: On +7 day after chemotherpay
  2. Induction regimen efficacy (DA-90 vs DAC) - II inductionTime frame: On +28 day after chemotherapy or after complete morphology regeneration (if it occurs before day +28)
  3. Salvage regimen efficacy (CLAG-M vs FLAG-IDA) - I reinductionTime frame: On +28 day after chemotherapy or after complete morphology regeneration (if it occurs before day +28)
  4. Salvage regimen efficacy (CLAG-M vs FLAG-IDA) - II reinductionTime frame: On +28 day after chemotherapy or after complete morphology regeneration (if it occurs before day +28)

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Weill Cornell Medicine

    New York, New York · Recruiting

  • Medical University of Bialystok Clinical Hospital

    Bialystok, Poland · Recruiting

  • Markiewicz Memorial Oncology Center Brzozow

    Brzozów, Poland · Recruiting

  • University Clinical Centre in Gdansk

    Gdansk, Poland · Recruiting

  • Holycross Cancer Center

    Kielce, Poland · Recruiting

  • Ludwik Rydygier Memorial Specialized Hospital

    Krakow, Poland · Recruiting

  • Regional Specialised Hospital in Legnica

    Legnica, Poland · Recruiting

  • Copernicus Memorial Hospital in Lodz Comprehensive Cancer Center and Traumatology

    Lodz, Poland · Recruiting

  • Independent Public University Hospital No. 1 in Lublin

    Lublin, Poland · Recruiting

  • Clinical Hospital at the Karol Marcinkowski Medical University in Poznan

    Poznan, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.